Efficacy of immune checkpoint inhibitors combined with different chemotherapy in recurrent pancreatic cancer: a retrospective study
ObjectiveRecurrence affects 65%-75% of pancreatic cancer (PC) patient post-resection. Established salvage strategies for recurrent PC are lacking, and systemic chemotherapy offers limited survival benefits. This study aimed to evaluate the efficacy and…